Medline (NASDAQ:MDLN) Now Covered by Analysts at Wolfe Research

Equities researchers at Wolfe Research started coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday. The firm set an “outperform” rating and a $47.00 price target on the stock. Wolfe Research’s price objective would indicate a potential upside of 15.99% from the company’s current price.

A number of other equities research analysts also recently weighed in on MDLN. Sanford C. Bernstein started coverage on Medline in a report on Monday. They set an “outperform” rating and a $49.00 price objective on the stock. Royal Bank Of Canada initiated coverage on Medline in a research report on Monday. They set an “outperform” rating and a $47.00 target price for the company. The Goldman Sachs Group set a $49.00 price objective on Medline and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley began coverage on shares of Medline in a report on Sunday. They set an “overweight” rating and a $48.00 price target for the company. Finally, Redburn Partners set a $42.00 price objective on shares of Medline in a research note on Monday. Eighteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $47.25.

Medline Price Performance

NASDAQ:MDLN opened at $40.52 on Monday. Medline has a 52 week low of $34.89 and a 52 week high of $45.50.

Insiders Place Their Bets

In other Medline news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. This trade represents a 55.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Andrew J. Mills bought 2,586,206 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were bought at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the transaction, the director directly owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.